Blood donor screening for parvovirus B19

Cohen, B. J.; Field, Anne M.; Guðnadóttir, Sigrún; Beard, Stuart; Barbara, J. A. J.

doi:10.1016/0166-0934(90)90065-n

Cited by 75 publications

(30 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, we have found that the prevalence of B19 infection in our allogeneic donor population was higher than reported previously [6, 7, 8]. However, in our study, the relatively high prevalence of B19 within the blood supply did not translate into an increased risk of disease within recipients of single unit products made from units containing B19-specific immunoglobulin.…”

Section: Discussioncontrasting

confidence: 54%

See 1 more Smart Citation

Human Parvovirus B19:& ;Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients

Jordan¹,

Tiangco²,

Kiss³

et al. 1998

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives: Blood donor units are not screened for human parvovirus B19 (B19) even though it can be acquired via blood products. We estimated the prevalence of B19 in a US volunteer blood donor population and determined the clinical outcomes of transfusion recipients. Materials and Methods: Donor units were screened for B19 DNA by PCR, and positive units analyzed by EIA for B19 Ig. Unit usage was determined and recipient chart review conducted. Results: B19 DNA was detected in 11/9, 568 allogeneic units (0.1%), of which 3 had no measurable B19 Ig. One individual developed anemia consistent with B19 infection after receiving a DNA+ unit lacking B19 Ig. Conclusions: The apparent low incidence of disease in patients transfused with B19 DNA+ components may be due to coexistence of neutralizing antibodies in donors and/or recipients.

show abstract

Section: Discussioncontrasting

confidence: 54%

“…The frequency of B19 viremia in voluntary blood donors has been estimated at rates of 1: 260 to 1: 40,000 [6, 7, 8, 9]. This wide range may relate in part to differences in the methods used to detect the virus, or it may reflect seasonal differences of the virus.…”

Section: Introductionmentioning

confidence: 99%

Human Parvovirus B19:& ;Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients

Jordan¹,

Tiangco²,

Kiss³

et al. 1998

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…Several assays are available for detecting B19 viremia, including double immunodiffusion (DID) [17], CIE [18], dot–blot hybridization [19], and PCR [20, 21]. Here, we report the results of a large–scale screening for the B19 virus by RHA.…”

Section: Discussionmentioning

confidence: 99%

Screening of Blood Donors for Human Parvovirus B19 and Characterization of the Results

Wakamatsu¹,

Takakura²,

Kojima³

et al. 1999

Vox Sanguinis

View full text Add to dashboard Cite

Background and Objectives: Human parvovirus B19 (B19 virus) can be transmitted through blood transfusion and plasma–derived products. In a previous report, we utilized the simple hemagglutination method based on the interaction between the B19 virus and P antigen on human erythrocytes in order to screen the blood donors. We called this method receptor–mediated hemagglutination (RHA) [Lancet 1995;346:1237–1238]. In this paper, we report on a large–scale screening of the B19 virus by RHA and discuss the results. Materials and Methods: Donor sera from September 1995 to March 1997 and seroconversion panels were enrolled. Donor sera were examined by RHA for large–scale screening. The positive sera in the first screening were then further investigated by the RHA inhibition test, countercurrent immunoelectrophoresis (CIE), an enzyme–linked immunosorbent assay, and polymerase chain reaction (PCR). We also evaluated the infectivity and neutralizing activity of various kinds of sera by the erythroid colony forming unit (CFU–e) assay. To examine the detection limits of the B19 virus by RHA, B19–viremic sera were purified by sucrose gradient ultracentrifugation. Results: Among 257,710 sera specimens, 293 sera (0.11%) gave a positive reaction in the first screening using RHA. Out of these 293 sera specimens, 31 were positive for PCR, of which 28 were also RHA inhibition–positive, and 25 of the 28 CIE–positive. In the CFU–e injury assay, all the RHA inhibition (+) sera showed a decrease in the number of erythroid colonies. The RHA inhibition (–) PCR (+) B19 antibody (+) sera did not affect the erythroid colony formation and protected CFU–e from injury by the B19 virus. By measuring the amount of purified B19 protein and its RHA titer, the detection limit of the B19 virus by RHA was calculated to the 0.37±0.03 ng/ml. Conclusion: These results suggest that the RHA(+) RHA inhibition (+) sera were infectious in vitro. The combination of RHA and the RHA inhibition test is considered to be useful for the large–scale screening of infectious B19 virus in blood donors with high specificity.

show abstract

“…Although antibody is highly prevalent in the general population, viraemia is rare. A study of the prevalence in blood donors showed that approximately 1 : 20 000-1 : 40 000 units of blood during epidemic seasons will show high titres of B19 (Cohen et al, 1990). …”

mentioning

confidence: 99%

Lack of Evidence for Parvovirus B19 Viraemia in Children With Chronic Neutropenia

et al. 1994

View full text Add to dashboard Cite

Blood donor screening for parvovirus B19

Cited by 75 publications

References 6 publications

Human Parvovirus B19:& ;Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients

Human Parvovirus B19:& ;Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients

Screening of Blood Donors for Human Parvovirus B19 and Characterization of the Results

Lack of Evidence for Parvovirus B19 Viraemia in Children With Chronic Neutropenia

Contact Info

Product

Resources

About